dimethyl sulfoxide has been researched along with Metastase in 49 studies
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.
dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the current study, we analyzed the combinatorial effect of MSM and tamoxifen on the suppression of ER-positive breast cancer xenograft growth and metastasis." | 7.81 | The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts. ( Chang, SH; Cho, BW; Darvin, P; Hwang, TS; Joung, YH; Kang, DY; Kim, DN; Kim, HS; Kim, SY; Kim, WS; Lee, HK; Park, JH; Park, KD; S P, N; Yang, YM; Yoo, YB, 2015) |
| "However, these therapeutic approaches are considered palliative at this stage, and their significant side effects can cause further decline in patients' quality of life and increase non-cancer-related morbidity/mortality." | 5.37 | Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer. ( Bui, NT; Ha, TV; Hoang, BX; Hoang, C; Le, BT; Pham, CQ; Pham, TD; Shaw, DG; Tran, DM; Tran, HD; Tran, HQ, 2011) |
| " (imH)[trans-RuCl(4)(dmso-S)(im)] (im = imidazole, dmso = dimethylsulfoxide), is a Ru(III) complex that, after extensive preclinical investigations that evidenced its remarkable and specific activity against metastases, has recently and successfully completed a Phase I trial (first ruthenium complex ever to reach clinical testing)." | 4.82 | Ruthenium antimetastatic agents. ( Alessio, E; Bergamo, A; Mestroni, G; Sava, G, 2004) |
| " We found that polar compounds and butyric acid, which are known to alter the expressions of normally silent genes, enhanced the lung-colonizing ability of cloned low-metastatic Lewis lung carcinoma cells." | 4.77 | Modification of the metastatic potential of tumor cells by drugs. ( Takenaga, K, 1986) |
| "In the current study, we analyzed the combinatorial effect of MSM and tamoxifen on the suppression of ER-positive breast cancer xenograft growth and metastasis." | 3.81 | The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts. ( Chang, SH; Cho, BW; Darvin, P; Hwang, TS; Joung, YH; Kang, DY; Kim, DN; Kim, HS; Kim, SY; Kim, WS; Lee, HK; Park, JH; Park, KD; S P, N; Yang, YM; Yoo, YB, 2015) |
| "The ruthenium-based drug NAMI-A, characterised by its selectivity against solid tumour metastases, promotes TGF-β1-dependent fibrosis and the reduction of the release of MMPs in the primary tumour." | 3.81 | Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process. ( Bergamo, A; Brescacin, L; Masi, A; Sava, G, 2015) |
| "Imidazolium-trans-dimethylsulfoxideimidazoletetrachlororuthenate (NAMI-A) is a ruthenium compound effective on solid tumor metastases." | 3.72 | Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration. ( Cocchietto, M; Sava, G; Sorc, A; Zorzet, S, 2003) |
| "NAMI-A is a novel ruthenium complex with selective activity against metastases currently in Phase I clinical trials in The Netherlands." | 3.71 | Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A. ( Beijnen, JH; Bouma, M; Bult, A; Jansen, MT; Nuijen, B; Sava, G, 2002) |
| "NAMI-A is a novel ruthenium complex with selective activity against cancer metastases currently in Phase I clinical trials in The Netherlands." | 3.71 | A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. ( Beijnen, JH; Bouma, M; Bult, A; Flaibani, A; Jansen, MT; Nuijen, B; Sava, G, 2002) |
| "In the present investigation we have determined the effects of the differentiation-inducing chemicals dimethyl sulfoxide (DMSO) and sodium butyrate on the growth and tumorigenicity of a highly malignant/metastatic cell line (RAW117-H10) and its less tumorigenic parental lymphoma cell line (RAW117-P)." | 3.67 | Effects of differentiation inducing chemicals on in vivo malignancy and NK susceptibility of metastatic lymphoma cells. ( Brunson, KW; Joshi, SS; Mathews, NB; Sharp, JG; Sinangil, F; Volsky, DJ, 1988) |
| "Metastases are more decisive for tumour prognosis than primary lesions, because of their multiple locations, low accessibility to surgery and/or radiotherapy, and generally poor responsiveness to chemotherapy." | 2.44 | Ruthenium complexes can target determinants of tumour malignancy. ( Bergamo, A; Sava, G, 2007) |
| "Overall, our study revealed a novel metastasis-promoting function of SOCS5 in HCC, acting via the PI3K/Akt/mTOR-mediated autophagy pathway." | 1.51 | SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway. ( Chua, MS; Han, B; Li, H; Liu, S; Luo, D; Sun, C; Wang, S; Zhang, M; Zhang, S, 2019) |
| "CAY10591 treatment dose- and time-dependently increased SIRT1 level and activity." | 1.46 | CAY10591, a SIRT1 activator, suppresses cell growth, invasion, and migration in gingival epithelial carcinoma cells. ( Mikami, Y; Murofushi, T; Suzuki, N; Tsuda, H; Yamaguchi, Y, 2017) |
| "Melanoma is a highly metastatic and lethal form of skin cancer." | 1.40 | BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. ( Cook, M; Girotti, MR; Gore, M; Hayes, A; Larkin, J; Lorigan, P; Marais, R; Niculescu-Duvaz, D; Pedersen, M; Sanchez-Laorden, B; Saturno, G; Springer, C; Turajlic, S; Viros, A; Zambon, A, 2014) |
| "However, these therapeutic approaches are considered palliative at this stage, and their significant side effects can cause further decline in patients' quality of life and increase non-cancer-related morbidity/mortality." | 1.37 | Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer. ( Bui, NT; Ha, TV; Hoang, BX; Hoang, C; Le, BT; Pham, CQ; Pham, TD; Shaw, DG; Tran, DM; Tran, HD; Tran, HQ, 2011) |
| " The main reason is that the drug's hydrophobicity hinders its bioavailability in the body fluids." | 1.34 | Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration. ( Bergamante, V; Carosio, R; Cilli, M; Gotti, R; Montaldo, PG; Orienti, I; Zuccari, G, 2007) |
| "This paper describes the development of a stable pharmaceutical dosage form for NAMI-A, a novel antimetastatic ruthenium complex, for Phase I testing." | 1.31 | Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A. ( Beijnen, JH; Bouma, M; Bult, A; Flaibani, A; Kettenes-van den Bosch, JJ; Nuijen, B; Perbellini, A; Sava, G; Talsma, H; van Steenbergen, MJ, 2002) |
| " These data indicated that NAMI-A is well absorbed after oral administration although there is no connection between lung concentration and the antimetastatic activity." | 1.30 | Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice. ( Alessio, E; Capozzi, I; Clerici, K; Cocchietto, M; Gagliardi, R; Marrella, M; Mestroni, G; Milanino, R; Sava, G, 1998) |
| "The line 1 lung carcinoma is a spontaneous murine tumor deficient in class I antigen expression." | 1.28 | Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection. ( Blieden, TM; Cerosaletti, KM; Frelinger, JG; Harwell, LW; Lord, EM; Welsh, KM, 1990) |
| "Dimethyl sulfoxide-treated P-29 cells were trapped in the lung more than untreated cells and were cleared from the lungs more slowly than untreated cells." | 1.27 | Enhanced metastatic potential of cloned low-metastatic Lewis lung carcinoma cells treated in vitro with dimethyl sulfoxide. ( Takenaga, K, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (26.53) | 18.7374 |
| 1990's | 6 (12.24) | 18.2507 |
| 2000's | 18 (36.73) | 29.6817 |
| 2010's | 12 (24.49) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 1 |
| Liu, S | 1 |
| Chua, MS | 1 |
| Li, H | 1 |
| Luo, D | 1 |
| Wang, S | 1 |
| Zhang, S | 1 |
| Han, B | 1 |
| Sun, C | 1 |
| Murofushi, T | 1 |
| Tsuda, H | 1 |
| Mikami, Y | 1 |
| Yamaguchi, Y | 1 |
| Suzuki, N | 1 |
| Ponnapakkam, T | 1 |
| Saulsberry, T | 1 |
| Hill, T | 1 |
| Hill-Odom, M | 1 |
| Goyal, N | 1 |
| Anbalagan, M | 1 |
| Liu, J | 1 |
| Foroozesh, M | 1 |
| Sanchez-Laorden, B | 1 |
| Viros, A | 1 |
| Girotti, MR | 1 |
| Pedersen, M | 1 |
| Saturno, G | 1 |
| Zambon, A | 1 |
| Niculescu-Duvaz, D | 1 |
| Turajlic, S | 1 |
| Hayes, A | 1 |
| Gore, M | 1 |
| Larkin, J | 1 |
| Lorigan, P | 1 |
| Cook, M | 1 |
| Springer, C | 1 |
| Marais, R | 1 |
| S P, N | 1 |
| Darvin, P | 1 |
| Yoo, YB | 1 |
| Joung, YH | 1 |
| Kang, DY | 1 |
| Kim, DN | 1 |
| Hwang, TS | 1 |
| Kim, SY | 1 |
| Kim, WS | 1 |
| Lee, HK | 1 |
| Cho, BW | 1 |
| Kim, HS | 1 |
| Park, KD | 1 |
| Park, JH | 1 |
| Chang, SH | 1 |
| Yang, YM | 1 |
| Brescacin, L | 1 |
| Masi, A | 1 |
| Sava, G | 17 |
| Bergamo, A | 8 |
| Caron, JM | 4 |
| Mu, C | 1 |
| Chang, SW | 1 |
| Prosser, KE | 1 |
| Leung, AW | 1 |
| Santacruz, S | 1 |
| Jang, T | 1 |
| Thompson, JR | 1 |
| Yapp, DT | 1 |
| Warren, JJ | 1 |
| Bally, MB | 1 |
| Beischlag, TV | 1 |
| Walsby, CJ | 1 |
| Antonarakis, ES | 1 |
| Emadi, A | 1 |
| Bannon, M | 1 |
| Rosshirt, L | 1 |
| Luis, J | 1 |
| Monteagudo, L | 1 |
| Sternstein, GM | 1 |
| Hoang, BX | 1 |
| Le, BT | 1 |
| Tran, HD | 1 |
| Hoang, C | 1 |
| Tran, HQ | 1 |
| Tran, DM | 1 |
| Pham, CQ | 1 |
| Pham, TD | 1 |
| Ha, TV | 1 |
| Bui, NT | 1 |
| Shaw, DG | 1 |
| Guidi, F | 1 |
| Modesti, A | 1 |
| Landini, I | 1 |
| Nobili, S | 1 |
| Mini, E | 1 |
| Bini, L | 1 |
| Puglia, M | 1 |
| Casini, A | 1 |
| Dyson, PJ | 1 |
| Gabbiani, C | 1 |
| Messori, L | 1 |
| Bouma, M | 4 |
| Nuijen, B | 4 |
| Jansen, MT | 3 |
| Bult, A | 4 |
| Beijnen, JH | 4 |
| Perbellini, A | 1 |
| Flaibani, A | 3 |
| van Steenbergen, MJ | 1 |
| Talsma, H | 1 |
| Kettenes-van den Bosch, JJ | 1 |
| Picotti, F | 1 |
| Cocchietto, M | 4 |
| Zorzet, S | 3 |
| Sorc, A | 2 |
| Stocco, G | 1 |
| Casarsa, C | 1 |
| Alessio, E | 7 |
| Serli, B | 1 |
| Bacac, M | 2 |
| Hotze, AC | 1 |
| van der Schilden, K | 1 |
| Haasnoot, JG | 1 |
| Pacor, S | 3 |
| Reedijk, J | 1 |
| Mestroni, G | 4 |
| Vadori, M | 1 |
| Ravera, M | 1 |
| Baracco, S | 1 |
| Cassino, C | 1 |
| Zanello, P | 1 |
| Osella, D | 1 |
| Bicek, A | 1 |
| Turel, I | 1 |
| Kanduser, M | 1 |
| Miklavcic, D | 1 |
| Orienti, I | 1 |
| Zuccari, G | 1 |
| Bergamante, V | 1 |
| Carosio, R | 1 |
| Gotti, R | 1 |
| Cilli, M | 1 |
| Montaldo, PG | 1 |
| Griffith, D | 1 |
| Cecco, S | 1 |
| Zangrando, E | 1 |
| Marmion, CJ | 1 |
| Pan, XB | 1 |
| Han, JC | 1 |
| Wei, L | 1 |
| Peng, DD | 1 |
| Gao, Y | 1 |
| Cohn, I | 1 |
| Takenaga, K | 4 |
| Fuks, JZ | 1 |
| Egorin, MJ | 1 |
| Aisner, J | 1 |
| Ostrow, SS | 1 |
| Klein, ME | 1 |
| Bachur, NR | 1 |
| Colvin, M | 1 |
| Wiernik, PH | 1 |
| Zolfaghari, A | 1 |
| Djakiew, D | 1 |
| Gagliardi, R | 1 |
| Clerici, K | 1 |
| Capozzi, I | 1 |
| Marrella, M | 1 |
| Milanino, R | 1 |
| Gava, B | 1 |
| Iengo, E | 1 |
| Vacca, A | 1 |
| Bruno, M | 1 |
| Boccarelli, A | 1 |
| Coluccia, M | 1 |
| Ribatti, D | 1 |
| Garbisa, S | 1 |
| Sartor, L | 1 |
| Cerosaletti, KM | 1 |
| Blieden, TM | 1 |
| Harwell, LW | 1 |
| Welsh, KM | 1 |
| Frelinger, JG | 1 |
| Lord, EM | 1 |
| Sala, A | 1 |
| Benedetto, A | 1 |
| Elia, G | 1 |
| Pulciani, S | 1 |
| Ciotta, C | 1 |
| Parlanti, E | 1 |
| Santodonato, L | 1 |
| Belardelli, F | 1 |
| Bentel, JM | 1 |
| Rhodes, GC | 1 |
| Markus, I | 1 |
| Smith, GJ | 1 |
| Ossowski, L | 1 |
| Nakamura, Y | 1 |
| Sakiyama, S | 1 |
| Joshi, SS | 1 |
| Sinangil, F | 1 |
| Sharp, JG | 1 |
| Mathews, NB | 1 |
| Volsky, DJ | 1 |
| Brunson, KW | 1 |
| Young, MR | 1 |
| Duffie, GP | 1 |
| Newby, M | 1 |
| Tucker, EJ | 1 |
| Carrizo, A | 1 |
| Sander, J | 1 |
| Bürkle, G | 1 |
| Bürkle, V | 1 |
| Glaser, FH | 1 |
| Ayre, JE | 1 |
| LeGuerrier, J | 1 |
5 reviews available for dimethyl sulfoxide and Metastase
| Article | Year |
|---|---|
Ruthenium-based chemotherapeutics: are they ready for prime time?
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dimethyl Sulfoxide; Drug Screening Assays, | 2010 |
Ruthenium anticancer drugs.
Topics: Antineoplastic Agents; Cell Cycle; Dimethyl Sulfoxide; Humans; Mitogen-Activated Protein Kinases; Ne | 2004 |
Ruthenium antimetastatic agents.
Topics: Antineoplastic Agents; Dimethyl Sulfoxide; Humans; Ligands; Molecular Conformation; Neoplasm Metasta | 2004 |
Ruthenium complexes can target determinants of tumour malignancy.
Topics: Animals; Antineoplastic Agents; Dimethyl Sulfoxide; Drug Design; Humans; Mice; Molecular Structure; | 2007 |
Modification of the metastatic potential of tumor cells by drugs.
Topics: Animals; Azacitidine; Butyrates; Butyric Acid; Carcinoma; Cell Division; Cell Line; Cells, Cultured; | 1986 |
44 other studies available for dimethyl sulfoxide and Metastase
| Article | Year |
|---|---|
SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dimethyl Sulfoxide; | 2019 |
CAY10591, a SIRT1 activator, suppresses cell growth, invasion, and migration in gingival epithelial carcinoma cells.
Topics: Cell Division; Cell Line, Tumor; Cyclopentanes; Dimethyl Sulfoxide; Gingival Neoplasms; Humans; Neop | 2017 |
Inhibition of breast tumor growth in mice after treatment with ceramide analog 315.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Ceramides; Dimethyl Sulfoxide; F | 2018 |
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.
Topics: Animals; Blotting, Western; Cell Shape; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Enzyme-Linked | 2014 |
The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferati | 2015 |
Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Huma | 2015 |
Methyl Sulfone Blocked Multiple Hypoxia- and Non-Hypoxia-Induced Metastatic Targets in Breast Cancer Cells and Melanoma Cells.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Child, Preschool; Dimethyl Sulfoxide; Female; Humans; Iron; | 2015 |
Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.
Topics: Crystallography, X-Ray; Dimethyl Sulfoxide; Electron Spin Resonance Spectroscopy; Ferrous Compounds; | 2016 |
Methyl sulfone induces loss of metastatic properties and reemergence of normal phenotypes in a metastatic cloudman S-91 (M3) murine melanoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cellular Senescence; Dimethyl Sulfo | 2010 |
Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Dimethyl Sulfoxide; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Met | 2011 |
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Down-Regulation; Hu | 2013 |
Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
Topics: Antineoplastic Agents; Dimethyl Sulfoxide; Drug Stability; Lighting; Neoplasm Metastasis; Organometa | 2002 |
Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Dimethyl Sulfoxide; Freeze Drying; Infusions, Pare | 2002 |
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Topics: Antineoplastic Agents; Dimethyl Sulfoxide; Drug Stability; Neoplasm Metastasis; Organometallic Compo | 2002 |
Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dimethyl Sulfox | 2003 |
Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antineoplastic Agents; Carcinom | 2003 |
Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Topics: Animals; Cell Line, Tumor; Collagen; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Drug Comb | 2004 |
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Topics: Antineoplastic Agents; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Chlorides; Dimethyl Sulfo | 2004 |
Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Coculture Techniques; Dimethyl Sulfoxide; Hyaluronan Rec | 2004 |
Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Topics: Antineoplastic Agents; Dimethyl Sulfoxide; Electrodes; Electrolysis; Magnetic Resonance Spectroscopy | 2004 |
Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dimethyl Sulfoxide; Electrochemothe | 2007 |
Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Dimet | 2007 |
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dimethyl Sulfox | 2008 |
[Subcellular distribution and translocation of hepatitis B virus core protein in HepG2.2.15 cells].
Topics: Chromosome Positioning; Dimethyl Sulfoxide; Hep G2 Cells; Hepatitis B Core Antigens; Hepatitis B vir | 2008 |
Implantation in cancer of the colon.
Topics: Animals; Antisepsis; Carcinoma, Brown-Pearce; Colonic Neoplasms; Dextrans; Dimethyl Sulfoxide; In Vi | 1967 |
Enhancement of lung-colonizing ability of cloned low-metastatic Lewis lung carcinoma cells by treatment with highly polar compounds.
Topics: Animals; Carcinoma; Cathepsins; Cell Adhesion; Cycloheximide; Dimethyl Sulfoxide; Lung Neoplasms; Mi | 1984 |
Enhanced metastatic potential of cloned low-metastatic Lewis lung carcinoma cells treated in vitro with dimethyl sulfoxide.
Topics: Animals; Cell Adhesion; Cell Aggregation; Cell Line; Clone Cells; Dimethyl Sulfoxide; Hydrolases; Ki | 1984 |
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.
Topics: Adult; Aged; Alkylating Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Dimethyl Sulfoxide; Drug | 1981 |
Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.
Topics: Alkaloids; Antibodies, Monoclonal; Carbazoles; Carcinogens; Carcinoma; Cell Movement; Dimethyl Sulfo | 1996 |
Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis; Dimethyl Sulfoxide; Female; Lun | 1998 |
Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Topics: Animals; Antineoplastic Agents; Collagen; Dimethyl Sulfoxide; Drug Combinations; G2 Phase; Humans; L | 2000 |
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cells, Cultured; Chemotaxis; Dimethyl Sulfoxide; End | 2002 |
Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.
Topics: Animals; Antineoplastic Agents; Cisplatin; Dimethyl Sulfoxide; Drug Administration Schedule; Female; | 1992 |
Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection.
Topics: Animals; Carcinoma; Cytotoxicity, Immunologic; Dimethyl Sulfoxide; Histocompatibility Antigens Class | 1990 |
Growth properties, differentiation capacity and oncogene expression in metastatic and nonmetastatic Friend leukemia cell variants.
Topics: Acetamides; Animals; Cell Differentiation; Cell Division; Dimethyl Sulfoxide; Friend murine leukemia | 1991 |
Enhanced invasiveness and metastatic potential of epithelial cell lines cultured in the presence of dimethyl sulphoxide.
Topics: Animals; Cell Line; Clone Cells; Dimethyl Sulfoxide; Epithelium; Immune Tolerance; Mice; Mice, Inbre | 1990 |
Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo.
Topics: Allantois; Animals; Catalysis; Chick Embryo; Chorion; Dimethyl Sulfoxide; Humans; Immunoglobulin G; | 1988 |
Differential expression of a tropomyosin isoform in low- and high-metastatic Lewis lung carcinoma cells.
Topics: Animals; Butyrates; Butyric Acid; Cell Division; Dimethyl Sulfoxide; Electrophoresis, Polyacrylamide | 1988 |
Effects of differentiation inducing chemicals on in vivo malignancy and NK susceptibility of metastatic lymphoma cells.
Topics: Animals; Butyrates; Butyric Acid; Cell Differentiation; Cell Division; Cell Line; Cytotoxicity, Immu | 1988 |
Adhesiveness and morphology of Lewis lung carcinoma variants influence their sensitivity to natural killer cytolysis and their metastatic capacity.
Topics: Animals; Cell Adhesion; Clone Cells; Cytochalasin B; Cytotoxicity, Immunologic; Dimethyl Sulfoxide; | 1987 |
Haematoxylon dissolved in dimethylsulfoxide used in recurrent neoplasms.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Dimethyl Sulfoxide; Dogs; Drug Synergism; Female; Horse | 1968 |
[Induction of lungtumors and tumors of the urinary bladder in rats by di-n-butyl nitrosamine in dimethyl sulfoxide].
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Dimethyl Sulfoxide; Drug Interactions; Injections | 1974 |
[On the use of dimethyl sulphoxide (DMSO) in radiation therapy (author's transl)].
Topics: Adolescent; Adult; Child, Preschool; Dimethyl Sulfoxide; Female; Humans; Keloid; Male; Middle Aged; | 1973 |
Some (regressive) effects of DMSO dexamethasone upon cervical cells in cervical dysplasia and carcinoma in situ.
Topics: Barium; Carcinoma; Chlorides; Contraceptive Devices; Dexamethasone; Dimethyl Sulfoxide; Female; Huma | 1967 |